How 3D Printing Medicine Creates Custom Drugs

Three-dimensional printing is moving from prototyping plastic parts to manufacturing actual medication, tablet by tablet, tailored to individual patients. The technology allows pharmacists and researchers to fabricate pills with precise doses, custom shapes, and engineered release profiles that conventional mass manufacturing cannot easily achieve. Some compounding pharmacies around the world have already begun incorporating 3D printing into standard practice, and hospital-based printing of personalized medicines is now the subject of active clinical trials. The field is still young, but the pace of development across oral dosage forms, implants, and even bioprinted tissue models for drug testing suggests this is not a niche curiosity.

How a Printer Makes a Pill

Most pharmaceutical 3D printing relies on extrusion, which works on the same basic principle as a desktop 3D printer laying down melted plastic. The most extensively studied method pairs hot melt extrusion with fused deposition modeling. In this process, a drug is blended with pharmaceutical-grade polymers and pushed through a heated nozzle to create a filament, which the printer then deposits layer by layer into the shape of a tablet.¹ The temperatures involved can reach 150°C or higher, which is fine for heat-stable drugs but problematic for molecules that break down under heat.²

For drugs that are sensitive to heat, semi-solid extrusion is the more common alternative. Instead of melting a filament, a paste or gel containing the drug is pushed through a syringe-like nozzle at room temperature or mildly elevated temperatures.³ This opens the door to biologics and other fragile compounds that would be destroyed in a conventional hot-melt setup. Both approaches share the advantage of building a dosage form from the ground up, which means the internal architecture of the tablet is a design choice, not a manufacturing accident.

Shape as a Drug Delivery Tool

One of the most counterintuitive findings in this field is that the geometry of a tablet, not just what is in it, can determine how fast the drug is released. Researchers have printed paracetamol tablets in mesh, ring, and solid forms from a single paste-based formulation containing over 80% drug by weight. The mesh tablets released the drug almost immediately, while the solid ones sustained release over a longer period. The difference came down to the ratio of surface area to volume: tablets with a larger ratio dissolved faster.⁴ Earlier work had shown the same dependency, confirming that shape, rather than surface area alone, is the controlling factor in how quickly a printed tablet gives up its contents.⁵

This matters because it means a pharmacist could, in principle, print two tablets with the exact same drug and the exact same formulation, but engineer one for rapid relief and the other for slow, steady delivery simply by choosing different internal structures. With conventional manufacturing, achieving that kind of flexibility typically requires reformulating with different excipients, coatings, or matrix systems. The geometric approach is far more elegant and potentially cheaper to implement at small scale.

Researchers have also used geometry to create gastroretentive tablets, designed to float in the stomach and release a drug slowly where it is best absorbed. By coupling hot melt extrusion with 3D printing, one group developed floating tablets of cinnarizine, a motion-sickness drug with a narrow absorption window, using hollow internal structures that trap air and keep the tablet buoyant.⁶

Polypills That Release Multiple Drugs on Schedule

People who take several medications daily, common among older adults managing blood pressure, cholesterol, and blood sugar, face a well-documented problem with adherence. Combining all of those drugs into a single tablet sounds straightforward, but each drug may need to be released at a different time or rate. A blood pressure drug might need sustained release over hours, while a pain reliever should kick in quickly. Conventional tablet presses struggle with that level of internal complexity.

3D printing makes it possible to place different drugs in physically separate compartments within one tablet, each engineered with its own release profile. Researchers have fabricated dual-drug tablets containing paracetamol and felodipine, then demonstrated that by rearranging the geometry and the positioning of each drug’s material within the tablet, they could achieve simultaneous, delayed, or pulsatile release from a single dosage form.⁷ The concept extends naturally to three or more drugs, though the engineering challenge scales with each additional active ingredient.

Children and Rare Diseases

Pediatric dosing is notoriously difficult. Most commercial tablets come in adult-sized doses. Pharmacists routinely split pills, crush them into powders, or compound liquid formulations, all of which introduce imprecision and palatability problems. 3D printing addresses both issues: the dose can be adjusted by simply changing the size of the printed tablet, and the appearance and taste can be engineered to be appealing to children. Tablets can be made in eye-catching shapes and with favorable flavors.⁸

A clinical study evaluated 3D printed chewable medicines containing amino acids for children with rare metabolic disorders. Six children received personalized doses of citrulline, isoleucine, valine, or combinations, with the dose in each tablet adjusted by altering the tablet size to match concentrations measured from blood samples. The study compared the 3D printed medicines against conventional compounded versions for both efficacy and acceptability.⁹ This kind of fine-tuned dosing, where the prescription drives the manufacturing in real time, is essentially impossible with standard pills off a factory line. For rare diseases, where patient populations are tiny and commercial incentives for mass production are weak, the ability to print medication on demand is especially compelling.

Acceptability testing with children backs up the promise. In a feasibility study of 30 participants, 87% successfully swallowed the 3D printed tablet they attempted, and 93% rated the taste as acceptable. About 77% said they would be happy to take the tablet daily, and when asked to compare the 3D printed versions with conventional film-coated tablets, the most common answer was that both were equally acceptable.¹⁰

What Adults Think About Printed Pills

The acceptability question is not limited to children. If patients are uncomfortable taking a pill that was printed rather than pressed, the technology will not get far. In a pilot study with 50 adult participants, researchers tested ten different printlet shapes including spheres, toruses (donut shapes), discs, capsules, and tilted diamonds. The torus scored highest for both ease of swallowing and ease of picking up. Shapes that resembled conventional tablets, like capsules and discs, also performed well, suggesting that familiarity with a form factor matters. Spheres, on the other hand, were not perceived as appropriate for oral medication. Smaller sizes and certain colors also influenced perception.¹¹

Separate work with patients on multiple daily medications found that aesthetic appeal, ease of swallowing, practical handling, understanding of the medication, and psychological connection to the treatment all influenced willingness to use 3D printed medicines.¹² The upshot is that patients are generally open to printed pills, but the design choices are not trivial. A strange-looking tablet can undermine trust in a way that conventional pharmaceuticals rarely do, simply because patients have decades of familiarity with standard pill shapes.

Implants That Deliver Drugs Locally

3D printing in medicine extends well beyond oral tablets. Drug-eluting implants, devices placed at a specific site in the body to release medication over weeks or months, benefit enormously from the ability to customize shape and drug-loading patterns. A printed implant can be designed to match the exact contours of a patient’s bone defect, wound cavity, or tumor resection site, while also delivering antibiotics, chemotherapy agents, or anti-inflammatory drugs directly where they are needed.¹³ The printing process allows region-specific drug loading, meaning different zones of the same implant can carry different drugs or different concentrations, creating architectures that would be difficult or impossible to achieve through molding or machining.¹⁴

Bioprinted Tissue for Drug Testing

A less obvious application sits upstream from the pharmacy entirely: using 3D bioprinting to create miniature human tissue models for screening drug toxicity. A research group fabricated a humanized liver model using hepatocytes derived from human fibroblasts, embedded in a bioink that mimics the natural cellular environment. These printed livers exhibited functions you would expect from real liver tissue, including albumin expression, glycogen storage, and the uptake and release of diagnostic compounds. When exposed to acetaminophen (the active ingredient in many over-the-counter pain relievers), the bioprinted livers showed heightened sensitivity to liver damage, making them a promising platform for studying drug-induced liver injury before a compound ever enters a human trial.¹⁵ If these models prove reliable at scale, they could reduce the need for animal testing in early drug development and provide more human-relevant safety data.

Printing in the Hospital Pharmacy

For 3D printed medicines to have real impact, they need to be manufactured where patients are, not just in research labs. Several groups are working on point-of-care models where a hospital pharmacy houses a printer and produces tablets on demand. One team demonstrated the first automated blister-filling workflow using a pharmaceutical 3D printer within a hospital pharmacy, spanning from manufacturing and dispensing to direct administration to patients. The specific application was baclofen lozenges for patients with swallowing difficulties, printed in personalized doses.¹⁶

At Gustave Roussy Cancer Campus in France, researchers produced 3D printed capsules containing tamoxifen for a clinical trial and tested handheld near-infrared and Raman spectrometers to verify the drug content without destroying the capsule. Both devices yielded highly accurate predictions, and the team demonstrated a “hub-and-spoke” model where calibration samples are prepared at a central research site and the production happens at the hospital pharmacy.¹⁷ This addresses one of the hardest practical questions: how do you prove that the pill the printer just made actually contains the right amount of drug?

Quality Control Without Breaking the Pill

Quality assurance is the unglamorous but critical bottleneck. Traditional pharmaceutical manufacturing verifies drug content by dissolving a batch sample and running it through analytical chemistry. When you are printing individual personalized doses, you cannot destroy the pill to test it, because that pill was made for one specific patient. Non-destructive testing is essential.

Near-infrared spectroscopy has emerged as the leading candidate for this role. A low-cost, compact NIR device was shown to function as a real-time dose-verification method at the point of care, enabling what researchers call “real-time release” of 3D printed medicines in a clinical setting.¹⁸ In another study, a portable NIR spectrometer was used to verify the doses of two separate active ingredients, amlodipine and lisinopril, within a single printed polypill. The calibration models showed excellent accuracy and specificity for both drugs, which the authors described as overcoming a major barrier to integrating 3D printing into clinical practice.¹⁹

Stability and Formulation Challenges

Printing a drug is not as simple as loading any compound into any polymer and pressing go. The heat and shear forces involved in extrusion can change the physical form of the drug, sometimes intentionally and sometimes not. During fused deposition modeling of escitalopram oxalate, researchers found that the drug converted from a crystalline to an amorphous form during the printing process itself. In one polymer system this happened during extrusion, while in another it occurred during the printing step.²⁰ Whether this amorphization is a feature or a problem depends on the drug: amorphous forms often dissolve faster but can be less stable during storage.

Drug-polymer compatibility is another challenge. In studies of common polymer-drug combinations, some pairings showed a protective effect where the polymer matrix actually delayed drug decomposition. Others showed clear signs of thermal instability and chemical breakdown, with paracetamol combined with polyvinyl alcohol being one example of a poor match.²¹ Getting the formulation right requires careful screening, and the research literature is still building the knowledge base for which combinations work and which do not.

Veterinary Medicine

Animals present many of the same dosing challenges as children: a Great Dane and a Chihuahua need very different amounts of the same drug, and neither is particularly cooperative about swallowing a bitter pill. 3D printing offers a way to produce personalized veterinary doses at the point of care. Semi-solid extrusion printers have been shown to produce smooth, flexible drug-loaded films with high dose accuracy and a strong correlation between the intended and actual drug amount.²²

One group took this a step further by using peanut butter as the primary matrix for printing chewable prednisolone tablets for companion animals. The printed treats had excellent dose linearity, immediate drug release, and mechanical properties designed to encourage voluntary oral intake. The approach bypasses the standard veterinary workaround of hiding pills in food, which is unreliable and can affect drug absorption.²³ It is a small but telling example of how the technology can solve practical problems that mass manufacturing has little commercial incentive to address.

Environmental Footprint

Any new manufacturing process invites questions about sustainability. A study measuring the energy consumption and carbon footprint of pharmaceutical 3D printing found that carbon emissions ranged from roughly 12 to 112 grams of CO₂ equivalent per 10 printed tablets, depending on the process parameters. That range was comparable to traditional tableting methods. The study also found that reducing the printing temperature substantially cut energy demand, suggesting that developing formulations printable at lower temperatures is an easy win for reducing emissions.²⁴

Separate work explored how machine learning could optimize printing parameters to minimize wasted material and reduce trial-and-error in formulation development, both of which contribute to the environmental cost of the research phase rather than the production phase.²⁵ The overall picture is reassuring: 3D printing is not inherently dirtier than conventional pharmaceutical manufacturing, and its per-tablet footprint could shrink as formulations and processes mature.

Orphan Drugs and Small-Batch Production

Perhaps the most underappreciated niche for pharmaceutical 3D printing is in orphan drugs, medications for diseases so rare that patient populations may number in the hundreds or low thousands. Traditional pharmaceutical manufacturing is built for scale. The economics of tableting, coating, and packaging are optimized for runs of millions of units. For a drug that might serve 500 patients worldwide, those economics do not work, which is one reason many approved orphan-drug molecules still have poor commercial formulations.

3D printing sidesteps scale. A small number of tablets can be produced without retooling a production line, and the technology can also improve the formulation itself. Researchers demonstrated that a fused deposition modeling approach could significantly improve the dissolution of rufinamide, a water-insoluble orphan drug for epilepsy. By blending the drug with specific polymers and excipients, the printed tablet dissolved substantially better than the commercial product at the same therapeutic dose. The combination of solid-dispersion technology with small-batch capability makes 3D printing a natural fit for drugs that the mainstream pharmaceutical industry finds economically unattractive to optimize.

The framework for clinical trials involving 3D printed medicines is also taking shape. Researchers have published guidance on how to design and run trials where the investigational product is printed at the point of care rather than shipped from a central manufacturing facility.²⁶ Establishing that regulatory pathway is a prerequisite for any of this technology moving from research curiosity to routine clinical use. The gap between what printers can do in a lab and what they are allowed to do in a hospital remains substantial, but it is closing.